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C-Reactive Protein Promotes 
Diabetic Kidney Disease in db/db 
Mice via the CD32b-Smad3-mTOR 
signaling Pathway
Yong-Ke You1,2, Xiao-Ru Huang2, Hai-Yong Chen2, Xia-Fei Lyu2, Hua-Feng Liu1 & Hui Y. Lan2
C-reactive protein (CRP) is associated with progressive diabetic nephropathy in patients with type-2 
diabetes (T2DN). However, role of CRP in T2DN remains unclear. We report here that CRP is pathogenic 
in T2DN in db/db mice that express human CRP (CRPtg-db/db). Compared to the littermate db/db 
mice, CRPtg-db/db developed more severe T2DN, showing higher levels of fasting blood glucose 
and microalbuminuria and more progressive renal inflammation and fibrosis. Enhanced T2DN in 
CRPtg-db/db mice were associated with over-activation of CRP-CD32b, NF-κB, TGF-β/Smad3, and 
mTOR signaling. Further studies in vitro defined that CRP activated Smad3 directly at 15 mins via the 
CD32b- ERK/p38 MAP kinase crosstalk pathway and indirectly at 24 hours through a TGF-β1-dependent 
mechanism. Importantly, CRP also activated mTOR signaling at 30 mins via a Smad3-dependent 
mechanism as Smad3 bound mTOR physically and CRP-induced mTOR signaling was abolished by a 
neutralizing CD32b antibody and a specific Smad3 inhibitor. Finally, we also found that CRP induced 
renal fibrosis through a CD32b-Smad3-mTOR pathway because blocking mTOR signaling with 
rapamycin inhibited CRP-induced CTGF and collagen I expression. Thus, CRP is pathogenic in T2DN. CRP 
may promote CD32b- NF-κB signaling to mediate renal inflammation; whereas, CRP may enhance renal 
fibrosis in T2DN via CD32b-Smad3-mTOR signaling.
Diabetes mellitus (DM) has become a major global health problem with high morbidity and mortality. Type 2 
diabetic nephropathy (T2DN) is one of the most important long-term microvascular complications of DM and 
becomes a leading cause of end-stage renal disease (ESRD) worldwide. Increasing evidence shows that T2DM is 
a low-grade inflammatory disease1. In patients with T2DM, serum levels of pro-inflammatory cytokines such as 
interleukin-1 beta (IL-1β ), interleukin-6 (IL-6), and CRP (C-reactive protein) are elevated and have been widely 
used as a biomarker of T2DM1–4. This is particularly important in those with DN5,6, suggesting a close relationship 
between inflammation and T2DM/T2DN.
CRP is an acute-phase protein and is rapidly synthesized and released in response to inflammation and tis-
sue damage7. In patients with T2DM, elevated serum levels of CRP are closely associated with an increase in 
microalbuminuria and renal dysfunction4,5, suggesting the close link between CRP and the development of DN. 
Among the inflammatory cascade, CRP can induce IL-6 via a NF-κ B-dependent mechanism8. We also found 
that under diabetic conditions, CRP is induced by high glucose, which in turn synergistically promotes high 
glucose-mediated renal inflammation and fibrosis in vitro and in a mouse model of streptozotocin-induced 
type-1 diabetes9. The functional importance for CRP is also demonstrated in other disease models including 
obstructive nephropathy10, ischemic kidney injury11, hypertensive heart disease12, and atherosclerosis13. However, 
the pathogenic role and regulatory mechanisms of CRP in T2DN remain unclear. Thus, the present study exam-
ined the pathogenic importance of CRP on T2DN by transgenically overexpressing human CRP in db/db mice. 
The mechanism whereby CRP promoted renal fibrosis through the CD32b-Smad3-mTOR mechanism was iden-
tified in vivo and in vitro.
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Results
CRP enhances fasting blood glucose and diabetic kidney injury in CRPtg-db/db mice. An equal 
high level of fasting blood glucose was demonstrated in both db/db and CRPtg-db/db mice at the age of week 
4; however, CRPtg-db/db mice developed higher levels of fasting blood glucose at week 16 onwards (Fig. 1A). 
This was associated with the development of the significant higher levels of microalbuminuria as determined by 
the urinary Albumin-to-Creatinine Ratio (UACR) in CRPtg-db/db mice over 16–36 weeks (Fig. 1B). However, 
compared to db/db mice, levels of serum creatinine and blood urea nitrogen were only marginally increased in 
Figure 1. CRPtg-db/db mice develop more severe diabetic renal functional and histological injury.  
(A) Fasting blood glucose. (B) Urinary albumin to creatinine ratio (UACR). (C) Periodic acid Schiff (PAS), 
Masson’ trichrome and periodic acid-silver methenamine (PASM) staining. (D,E) Quantitative analysis of 
mesangial expansion and glomerulosclerosis. Data represents the mean ± SEM for eight mice per group. 
Bar = 50 μ m. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with db/m mice; #p < 0.05, ##p < 0.01, ###p < 0.001 
compared with db/db mice.
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CRPtg-db/db mice (Supplementary Fig. S1). Histologically, periodic acid–Schiff (PAS), Masson trichrome, and 
Periodic Schiff-Methenamine Silver (PASM) staining revealed that db/db mice developed moderate mesangial 
matrix deposition, thickening of glomerular basement membrane, tubulointerstitial extracellular matrix accu-
mulation, and glomerulosclerosis when compared to the littermate db/m and CRPtg-db/m (Fig. 1C–E). All these 
pathological changes became much more severe in CRPtg-db/db mice (Fig. 1C–E).
Overexpression of CRP in db/db mice largely promotes renal inflammation and fibrosis. 
We then examined whether CRP-enhanced renal functional injury in db/db mice is associated with more 
severe renal inflammation and fibrosis, two major pathological features related to the development of DN. 
Immunohistochemistry and real-time PCR analysis revealed that compared with the littermates db/m 
and CRPtg-db/m control mice, db/db mice devolved moderate renal inflammation including a marked 
up-regulation of pro-inflammatory cytokines/chemokines (TNF-α , IL-1β , and MCP-1) and renal infiltration of 
F4/80+ macrophages and CD3+ T cells at the age of week 36 (Fig. 2 and Supplementary Fig. S2). All of these 
Figure 2. Renal inflammation is enhanced in CRPtg-db/db mice. (A–C) Real-time PCR analysis of 
pro-inflammatory cytokines of TNF-α , IL-1β , MCP-1, respectively. (D–F) Immunohistochemical staining 
and quantitative analysis of infiltration of CD3+ T cells and F4/80+ macrophage cells. Data represents the 
mean ± SEM for eight mice per group. Bar = 50 μ m. ** p < 0.01, *** p < 0.001 compared with db/m mice; 
##p < 0.01, ###p < 0.001 compared with db/db mice.
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inflammatory features in the diabetic kidney of db/db mice were largely exacerbated in CRPtg-db/db mice (Fig. 2 
and Supplementary Fig. S2). Further studies also revealed that moderate renal fibrosis such as expression of col-
lagen I and IV mRNA and their matrix protein accumulation in db/db mice at week 36 was also largely enhanced 
in CRPtg-db/db mice (Fig. 3).
Enhanced renal inflammation and fibrosis in CRPtg-db/db mice are associated with the acti-
vation of CD32b-NF-κB and CD32b-Smad3-mTOR signaling pathways. We next investigated 
the underlying signaling mechanisms by which CRP promotes diabetic kidney injury. Firstly, we examined 
plasma levels of CRP and its receptor, C32b. As shown in (Fig. 4), compared with db/m mice in which human 
CRP was undetectable, plasma levels of human CRP were moderate increased in CRPtg-db/m mice, which 
Figure 3. Renal fibrosis is enhanced in CRPtg-db/db mice. (A) Collagen I and collagen IV expression 
examined by immunohistochemistry. (B) Collagen I and collagen IV expression examined by Western blotting 
analysis. (C,D) Real-time PCR analysis of collagen 1 mRNA and collagen IV mRNA expression, respectively. 
Data represents the mean ± SEM for eight mice per group. Bar = 50 μ m. * *p < 0.01, * * * p < 0.001 compared with 
db/m mice; ##p < 0.01, ###p < 0.001 compared with db/db mice.
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was largely elevated in CRPtg-db/db mice (Fig. 4A). Real-time PCR, immunohistochemistry, and western blot 
analysis revealed a significant upregulation of CD32b in db/db, which was further increased in CRPtg-db/db 
mice. Expression of CD32b was primarily found in tubular epithelial cells and podocytes (Fig. 4C). Further 
study revealed that upregulation of CD32b in the diabetic kidney of db/db mice was associated with higher 
levels of phosphorylated p65 subunit and its nuclear translocation, which was further enhanced in CRPtg-db/db 
mice (Fig. 5), suggesting that CRP may promote renal inflammation in T2DN via a CD32b-NF-κ B signaling 
mechanism.
Figure 4. Expression of Fc gamma Receptor IIB (CD32b) is largely enhanced in the diabetic kidney of 
CRPtg-db/db mice. (A) Plasma levels of human CRP. (B) CD32b mRNA expression by real-time PCR.  
(C) CD32b expression pattern detected by immunohistochemical staining. Note that CD32b is highly expressed 
by tubular epithelial cells and podocytes (inserted picture) in CRPtg-db/db mice. (D) Quantitative analysis 
of CD32b expression. (E) Western blot analysis. Data represents the mean ± SEM for eight mice per group. 
Bar = 50 μ m. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with db/m mice; #p < 0.05, ###p < 0.001 compared 
with db/db mice.
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Interestingly, we also found that upregulation of CD32b in CRPtg-db/db mice was associated with a signifi-
cant upregulation of renal TGF-β 1 and CTGF at mRNA and protein levels (Supplementary Fig. S3), which was 
associated with enhanced Smad3 signaling as detected by higher levels of phosphorylated Smad3 and its nuclear 
localization in glomerular and tubulointerstitial cells (Fig. 6).
Because activation of mTOR has been shown to play an important role in the progression of DN in which 
TGF-β /Smad3 signaling is highly activated14–16, we examined the activation of mTOR signaling in the diabetic 
kidney by immunohistochemistry and western analysis. We found that like Smad3 signaling, phosphorylated 
mTOR was largely increased in the diabetic kidney of db/db mice, particularly in tubular epithelial cells and 
podocytes, which became much more profound in CRPtg-db/db mice (Fig. 6). All these findings suggested a close 
link of CD32b-Smad3-mTOR signaling in CRP-mediated T2DN.
CRP activates Smad3 via the CD32b-ERK/p-38 MAP kinase crosstalk pathway in vitro. Because 
TGF-β /Smad3 signaling was highly activated in the diabetic kidney associated with a marked upregulation of 
CD32b and severe renal fibrosis in CRPtg-db/db mice (Figs 3, 4, 6 and Supplementary Fig. S3), we hypothesized 
Figure 5. NF-κB signaling is significantly increased in CRPtg-db/db mice. (A) Immunohistochemical 
staining and quantitative analysis of nuclear phospho-NF-κ B/p65 (p-p65). (B) Western blot and quantitative 
analysis of phospho-NF-κ B/p65 (p-p65) protein. Data represents the mean ± SEM for eight mice per group. 
Bar = 50 μ m. ** p < 0.01, *** p < 0.001 compared with db/m mice; #p < 0.05, ###p < 0.001 compared with db/db 
mice.
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that CRP may activate Smad3 via the CD32b-dependent mechanism, which was investigated in vitro in HK-2 
tubular epithelial cells. We found that addition of CRP (10 μ g/ml) was able to induce Smad3 phosphorylation 
in a time-dependent manner, being significant as early as 15 mins (Fig. 7A), which was accompanied by a late 
response at 24 hours (Fig. 7C). Interestingly, CRP-induced Smad3 phosphorylation at 15 mins was associated with 
activation of the ERK1/2 and p38 (Fig. 7B), suggesting a link between ERK/p38 and Smad3 signaling. This was 
examined by treating CRP-stimulated HK-2 cells with ERK and p38 inhibitors. As shown in Fig. 7(D), addition of 
Figure 6. Smad3 and mTOR signaling is largely enhanced in the kidney of CRPtg-db/db mice.  
(A–C) Immunohistochemical staining of phospho-Smad3 and phospho-mTOR, respectively. (D,E) Western 
blot analysis of phospho-Smad3 and phospho-mTOR in the diabetic kidney, respectively. Data represents the 
mean ± SEM for eight mice per group. Bar = 50 μ m. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with db/m 
mice; #p < 0.05, ##p < 0.01, ###p < 0.001 compared with db/db mice.
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a neutralizing antibody to CD32b or inhibitors to ERK1/2 (PD98059) or p38 (SB203580) was capable of blocking 
CRP-induced Smad3 phosphorylation at 15 mins, revealing the CD32b-ERK/p38 MAP kinase crosstalk pathway 
in the early activation of Smad3 signaling in response to CRP. This was further confirmed by the inability of a 
neutralizing anti-TGF-β 1 antibody to block CRP-induced Smad3 phosphorylation at 15 mins, but not at 24 hours 
Figure 7. CRP induces activation of Smad3 directly via the CD32b-ERK/p38 MAP kinase-crosstalk 
pathway and indirectly through the TGF-β1-dependent mechanism in HK-2 cells. (A) p-Smad3 and 
p-mTOR, respectively. (B) p-ERK1/2 and p-p38, respectively. Data represents the mean ± SEM for at least 
three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with time 0. (C) HK-2 cells were 
pretreated with anti-TGF-β 1 neutralizing antibody (10 μ g/ml) or isotype control rabbit IgG (10 μ g/ml) for 
1 hour before stimulated with CRP (10 μ g/ml) for 15 minutes or 24 hours and examined for phosphorylation 
of Smad3 by western blots. Representative western blots and quantitation of p-Smad3 are shown. (D) HK-2 
cells were pretreated with anti-CD32b neutralizing antibody (5 μ g/ml), and specific inhibitors to ERK1/2 
(PD98059, 20 μ M), to p38 (SB203580, 10 μ M) for 1 hour before stimulated with CRP (10 μ g/ml) for 15 minutes. 
The phosphorylation of Smad3 was detected by western blot analysis. Data represents the mean ± SEM for at 
least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with normal group; #p < 0.05, 
##p < 0.01, ###p < 0.001 compared with addition of CRP.
www.nature.com/scientificreports/
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(Fig. 7C). Thus, CRP activated the early Smad3 signaling at 15 mins via the ERK/p38 MAP kinase crosstalk path-
way and the late Smad3 activation at 24 hours though a TGF-β 1-dependent mechanism.
CRP activates mTOR via a CD32b-Smad3-dependent mechanism in vitro. We next investigated 
signaling mechanism whereby CRP activates mTOR in HK-2 cells. By using an ECR browser17, we found a Smad3 
binding site on the UTR of mTOR gene (Fig. 8A). A ChIP assay also clearly detected the physical interaction of 
Smad3 with the UTR region of mTOR as identified by the ability of an antibody against Smad3 to successfully 
immunoprecipitate the DNA fragments that contain the potential Smad3 binding site in the UTR regions of 
mTOR, which was largely enhanced by CRP (Fig. 8B). The functional link between Smad3 and mTOR signaling 
was further demonstrated by the findings with quantitative flow cytometry, immunofluorescence, and western 
blot analysis that blockade of Smad3 signaling with a specific inhibitor (SIS3) was able to inhibit CRP-induced 
mTOR signaling in HK-2 cells in a dose-dependent manner (Fig. 8C, and Supplementary Figs S4 and S5), reveal-
ing a Smad3-mTOR signaling in response to CRP.
We have previously shown that high glucose is able to induce CRP expression by tubular epithelial cells9. Thus, 
we investigated the effect of CRP on activation of mTOR signaling under high glucose conditions. As shown in 
(Fig. 8D), addition of CRP (10 μ g/ml) or high glucose (35 mM), but not control mannitol (35 mM), was capable 
of activating mTOR as evidenced by a large increase in phosphorylated mTOR protein. Interestingly, the combi-
nation of CRP and high glucose did not additively increase mTOR signaling. However, addition of a neutralizing 
antibody to CD32b blunted both high glucose and CRP-induced mTOR signaling (Fig. 8D), implying that high 
glucose induces mTOR signaling via the CRP-CD32b-dependent mechanism. We also found that addition of CRP 
(10 μ g/ml) and/or high glucose (35 mM) for 6 hours could activate both mTOR and its substrate p70-S6 kinase, 
which was blocked by rapamycin (10 μ M), an mTOR inhibitor (Fig. 8E). Furthermore, blockade of mTOR sign-
aling with rapamycin was also able to inhibit CRP and /or high glucose-induced upregulation of collagen I and 
CTGF expression (Fig. 8F,G), demonstrating mTOR signaling as a central mechanism by which CRP promotes 
diabetic kidney disease in T2DN.
Discussion
We report here an important role of human CRP in Type 2 diabetic kidney disease as CRPtg-db/db mice devel-
oped much more progressive kidney injury including higher levels of hyperglycemia, microalbuminuria, and 
excessive renal inflammation and fibrosis.
We found that CRP promoted renal inflammation via the CD32b-NF-κ B-dependent mechanism, resulting 
in upregulation of TNF-α , IL-1β and MCP-1, and an increase in CD3+ T cell and F4/80+ macrophage infiltra-
tion in the diabetic kidney of CRPtg-db/db mice, revealing a role for CD32b-NF-κ B signaling in CRP-mediated 
renal inflammation. This finding was consistent with a known mechanism of NF-κ B in diabetic renal inflam-
mation9,18–24. Indeed, we have previously reported that human CRP can promote renal inflammation by activat-
ing NF-κ B signaling via the CD32/64-dependent mechanism in a mouse model of type 1 diabetic nephropathy 
induced in CRPtg mice and in vitro9. Again, the present study confirmed the CD32b-NF-κ B-dependent mecha-
nism in renal inflammation in T2DN induced in CRPtg-db/db mice.
A novel and significant finding in the present study was that CRP mediated renal fibrosis via the 
CD32b-Smad3-mTOR signaling pathway. Increasing evidence shows that activation of TGF-β /Smad signaling 
contributes to accumulation of the extracellular matrix, resulting in progressive renal fibrosis in both animal 
and human diabetic kidneys25–30. We have previously shown that under diabetic and hypertensive disease con-
ditions, AGEs and angiotensin II are capable of activating TGF-β /Smad3 signaling directly via the ERK/p38 
MAP kinase-crosstalk mechanism and indirectly by inducing TGF-β 31,32. The functional role for TGF-β /Smad3 
in diabetic kidney disease comes from recent studies that deletion of Smad3 protects against diabetic kidney 
disease29,33. Results from the present study added a new finding that CRP was able to induce the early phospho-
rylation of Smad3 and ERK1/2 and p38 at 15 mins in tubular epithelial cells, which was blocked by a neutralizing 
CD32b antibody and inhibitors to the ERK1/2 or p38. These findings demonstrate that CRP induced an early 
Smad3 signaling via the CD32b-ERK/p38 MAP kinase crosstalk pathway. This was further confirmed by the 
inability of addition of a neutralizing TGF-β 1 antibody to block the early activation of Smad3 in response to 
CRP. Because CRP alone is able to upregulate TGF-β 1 production by renal tubular epithelial cells in a time- and 
dosage-dependent manner9, addition of a neutralizing TGF-β 1 antibody was capable of inhibiting the late activa-
tion of Smad3 at 24 hrs after CRP stimulation, indicating a TGF-β 1-dependent mechanism in CRP-induced late 
activation of Smad3 signaling. Thus, CRP bound CD32b to activate Smad3 via both TGF-β 1-independent and 
dependent mechanism. This may account for the finding that activation of TGF-β 1/Smad3 signaling and renal 
fibrosis was significantly enhanced in the diabetic kidney of CRPtg-db/db mice. Interestingly, TGF-β 1 is capable 
of inhibiting IL-1β and IL-6-induced CRP production in a time and dosage-dependent manner34, suggesting a 
regulatory loop between CRP and TGF-β in renal fibrosis and inflammation. The interplay between CRP and 
TGF-β requires further investigation.
mTOR is a serine/threonine kinase that exists in two distinct signaling complexes known as mTOR Complex 
1 (mTORC1) and mTORC235. Emerging evidence shows that activation of mTOR plays a pivotal role in many 
kidney diseases including mesangial expansion, glomerular basement membrane thickening and tubuloint-
erstitial fibrosis in diabetic nephropathy14,15,36–41. Multiple studies have shown that mTOR can be activated by 
TGF-β and contributes to the profibrotic effect on matrix protein production16,42. In the present study, we found 
that there was a Smad3 binding site on the UTR region of mTOR and Smad3 could physically bind to mTOR 
as demonstrated by a ChiP assay and western blot. CRP alone was able to enhance Smad3-mTOR interaction 
and induce mTOR/S6K activation and renal fibrosis. Blockade of the CRP signaling with an anti-CD32b anti-
body or Smad3 signaling with a specific inhibitor (SIS3) was able to inhibit mTOR signaling, thereby attenuating 
renal fibrosis including mesangial expansion under high CRP conditions in vivo and in vitro. Thus, activation of 
www.nature.com/scientificreports/
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Figure 8. CRP induced Smad3 and mTOR signaling was blocked by a neutralizing CD32b antibody and a 
specific Smad3 inhibitor, and blockade of mTOR signaling with rapamycin inhibited CRP-induced collagen 
I expression. (A) Smad3-mTOR binding site. (B) ChIP assay detects the physical interaction between Smad3 
and mTOR, which is enhanced by addition of CRP (10 μ g/ml) in HK-2 cells. (C) HK-2 cells were pretreated 
with SIS3 (10 μ M) or DMSO for 1 hour before stimulated with CRP (10 μ g/ml) for 1 hour and examined for 
phosphorylation of mTOR by flow cytometry. Representative flow cytometry histograms and quantitative 
analysis of mean FITC intensity are shown. Data represents the mean ± SEM for at least three independent 
experiments. *p < 0.05, ** p < 0.01 compared with normal group; #p < 0.05 compared with addition of CRP. 
CRP and high glucose-induced activation of mTOR-p70S6K signaling and collagen I expression in HK-2 
cells is blocked by a neutralizing CD32b antibody and rapamycin. (D) Representative western blots show that 
addition of CRP (10 μ g/ml) or high glucose (35 mM) induces phosphorylation of mTOR, which is blocked by a 
neutralizing anti-CD32b antibody (5 μ g/ml). (E) Representative western blots show that addition of CRP  
(10 μ g/ml) or high glucose (35 mM) induces phosphorylation of mTOR and S6K, which is blocked by rapamycin 
(10 μ M). (F,G) Blocking mTOR signaling with rapamycin is able to inhibit CRP and/or high glucose-induced 
upregulation of collagen I (F) and CTGF expression (G). Data represents the mean ± SEM for at least three 
independent experiments. **p < 0.01, *** p < 0.001 compared with normal group; ##p < 0.01, ###p < 0.001 
compared with CRP group; §§§p < 0.001 compared with HG group; ††p < 0.01, †††p < 0.001 compared with 
CRP + HG group.
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CD32b-Smad3-mTOR signaling may be a key mechanism by which CRP mediates renal fibrosis. Interestingly, the 
combination of CRP and high glucose did not additively enhance mTOR signaling, but this was blocked by a neu-
tralizing antibody to CD32b, suggesting that high glucose may induce activation of mTOR via a CRP-dependent 
mechanism as high glucose is known to induce CRP9. The functional importance for the CD32b-Smad3-mTOR 
pathway in renal fibrosis was further demonstrated by the ability of rapamycin to inactivate the mTOR signaling, 
thereby inhibiting CRP and high glucose-induced CTGF and collagen I expression.
In conclusion, the present study demonstrates that CRP is pathogenic in type-2 diabetes and diabetic renal 
complication. CRP is capable of activating Smad3 signaling directly through the ERK/p38 MAP kinase-crosstalk 
pathway and indirectly via the TGF-β 1-dependent mechanism. CRP may promote renal inflammation via the 
CD32b-NF-κ B signaling mechanism, whereas, CRP may enhance renal fibrosis via the CD32b-Smad3-mTOR 
signaling pathway. Thus, results from this study suggest that targeting CRP may offer an alternative approach for 
prevention and treatment of diabetic kidney complication.
Materials and Methods
Animal model. Male db/db mice overexpressing human CRP (CRPtg-db/db) were used in this study. 
CRPtg-db/db mice were generated by crossbreeding db/m (C57BL/KSJ background) mice with human CRP trans-
genic mice (C57BL/6J background)7. Their littermates (CRPtg-db/m, WT-db/m and WT-db/db) were served as 
controls. The genotypes of mice were determined by genotyping of their tail DNA with specific CRP primers (for-
ward, 5′ -TTTACAGTGGGTGGGTCTGAAATA-3′ and reverse, 5′ -GGGCCACAGCTGGGGTTTGGTGAA-3′ ) 
and db/db primers (forward, 5′-AGAACGGACACTCTTTGAAGTCTC-3′ and reverse, 5′ -CATTCAA 
ACCATAGTTTAGGTTTGTGT-3′ ). While the serum levels of human CRP levels were determined by serum 
ELISA (R&D System, Minneapolis, MN, USA). Groups of eight male mice were euthanized at week 36 and the 
renal cortexes were collected for histology, immunohistochemistry, western blotting, and real-time PCR analysis. 
Blood plasma was collected by cardiac puncture in anaesthetized mice. All studies were approval by the Animal 
Experimentation Ethics Committee, the Chinese University of Hong Kong and the experimental methods were 
carried out in accordance with the approved guidelines.
Cell culture. The normal adult human TEC line, HK-2 cells, were cultured in serum-free DMEM (Dulbecco’s 
modified Eagle’s medium)/Ham’s F12 medium (Invitrogen Life Technologies, Gaithersburg, MD, USA) with 
recombinant human CRP (10 μ g/ml; R&D Systems, Minneapolis, MN, USA) for various periods of time to 
detect the activation of Smad3 and mTOR. To block the CRP-CD32b interaction or ERK1/2 and p38 activi-
ties, HK-2 cells were pretreated with an anti-CD32b neutralizing antibody ((5 μ g/ml; R&D), and specific inhib-
itors to ERK1/2 (PD98059, 20 μ M; Biomol), to p38 (SB203580, 10 μ M; Biomol) for 1 hour before addition of 
CRP (10 μ g/ml) for 15 minutes. To block Smad3 activation, HK-2 cell was treated with or without SIS3 (10 μ M, 
Sigma-Aldrich), a specific smad3 inhibitor for 1 hour before addition of CRP (10 μ g/ml). To determine whether 
activation of mTOR induced by CRP was enhanced under high glucose conditions, HK-2 cells were cultured in 
FBS-free medium for 24 hours and then stimulated with CRP (10 μ g/ml) under normal D-glucose (5.5 mM) or 
high D-glucose (35 mM) conditions for up to 6 hours, D-Mannitol (35 mmol/ml) was used as an osmotic con-
trol. To block CRP-mTOR signaling, HK-2 cells was treated with or without anti-CD32b neutralizing antibody 
(5 μ g/ml; R&D) or mTOR inhibitor, rapamycin (10 μ M; Sigma-Aldrich) for 1 hour before addition of CRP 
(10 μ g/ml). All the experiments were repeated independently for at least three times.
Fasting blood glucose. Blood glucose levels were measured by Accu-Chek glucose meter (Roche 
Diagnostics) after the mouse fasting for 6 hours as recommended by the Animal Models of Diabetic 
Complications Consortium43.
Renal Function Measurement. Urine was collected by housing individual mouse in the metabolic cages 
for 24 hours. A competitive ELISA method was used to detect the urine micro-albumin according to the manu-
facturer’s instruction (Exocell, Philadelphia, PA, USA).
Levels of blood urea nitrogen (BUN) and serum or urinary creatinine were determined accordingly with 
enzymatic method (Stanbio Laboratories, TX, USA).
Histopathology and Immunohistochemistry. Formalin-fixed, paraffin-sections (2–3 μ m) were stained 
with Periodic Acid-Schiff ’s (PAS) reagent and periodic acid-silver methenamine (PASM), Masson’s trichrome as 
previously described44. Immunohistochemistry was performed in paraffin sections by using a microwave-based 
antigen retrieval method45. The primary antibodies used in this study included as follows: TNF-α , IL-1β , TGF-β 1 
(Santa Cruz Biotechnology, Santa Cruz, CA), CD3 (eBioscience, San Diego, CA), F4/80 (AbD Serotec, Kidlington, 
UK), phospho-Smad3 (Rockland, Immuno-chemicals, Gilbertsville, PA), collagen I, collagen IV (Southern 
Biotech, Birmingham, AL), and Phospho- NF-κ B/p65 (Abcam, Cambridge, MA, USA), Phospho-mTOR 
(Ser2448) (Cell Signaling Technology, Danvers, MA). Fcγ RIIB/CD32b (R&D). Sections were counterstained with 
hematoxylin for the nuclei. Positive signals were quantitatively analyzed using the quantitative Image Analysis 
System (Image-Pro plus 7.0, Media Cybernetics, Bethesda, MD, USA) as described previously46.
To examine the activation of p-mTOR induced by CRP, HK-2 cells were incubated with p-mTOR antibody 
(Cell Signaling) for overnight at 4 °C, followed by the goat anti-rabbit FITC-conjugated IgG (Zymed Laboratories, 
San Francisco, CA) for 1 hour. Nuclei were counterstained with DAPI. The p-mTOR positive cells were identified 
under fluorescent microscope (DM60008, Leica microsystems Ltd., Germany).
Western blotting analysis. Protein from the kidney cortex or HK-2 cells was extracted and western blot 
analysis was performed as described previously47. Antibodies used in this study included: collagen I, collagen IV 
(Southern Biotech), CTGF, Phospho-p70s6k, p70s6k, β -actin (Santa Cruz), CD32b (R&D), Phospho- NF-κ B/
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p65, NF-κ B/p65, phospho-Smad3, Smad3, Phospho-mTOR (Ser2448), mTOR, Phospho-ERK1/2 MAPK, ERK1/2 
MAPK, Phospho-p38 MAPK, p38 MAPK (Cell Signaling), and LI-COR IRDye 800-labelled secondary antibodies 
(Rockland Immuno-chemicals). The detection of specific signals was performed by using the Odyssey infrared 
image system (LI-COR Biosciences, Lincoln, NE, USA) and quantified by Image J software (National Institutes 
of Health). The ratio for the protein detected was normalized against β -actin and expressed as the mean ± S.E.M.
RNA Extraction, Quantitative Real-Time PCR. Total RNA was extracted from the renal cortical 
tissues and cultured HK-2 cells and real-time PCR was performed with a real-time PCR machine (Option 2, 
Bio-Rad, Hercules, CA, USA) by using IQ SYBR green supermix reagent (Bio-Rad)47,48. The primers for mouse 
mRNA MCP-1, IL-1β , TNFa, collagen I, collagen IV, CD32 and human mRNA CTGF have been described previ-
ously9,10,48,49, The housekeeping genes β -actin was used as internal controls. The ratio of specific mRNA: β -actin 
mRNA was calculated using the 2−ΔΔCt method and is expressed as the mean ± S.E.M.
Chromatin immunoprecipitation analysis. Chromatin immunoprecipitation was performed 
as previously described48. Primary antibody against Smad3 (Cell Signaling) was used. Precipitated 
DNAs were detected by PCR using specific primers to detect the binding of Smad3 to mTOR: forward: 
5′ -GCAGCATCACTGGGTCTGAT-3′ , reverse: 5′ -GAAGATGCTGACCTCACCCC-3′ .
Flow cytometry. The HK-2 cells were treated with or without SIS3 (10 μ M) for 1 hour before addition of CRP 
(10 μ g/ml) for another 1 hour and examined for p-mTOR by flow cytometry. Briefly, the cells were fixed with 4% 
paraformaldehyde for 10 min and then permeabilized with 0.1% PBS-Tween 20 for 20 min and incubated with 
goat serum/PBS to block non-specific the anti-mTOR (phospho S2448) antibody (1:200; Abcam) at 4 °C over-
night, followed by FITC-labeled goat anti-rabbit IgG (1:2000; Zymed). Isotype rabbit IgG was used as negative 
control. Acquisition of 10000 events was collected.
Statistical analysis. All the data are expressed as the mean ± S.E.M. Statistical analyses were performed 
with one-way analysis of variance as appropriate, followed by Bonferroni’s post-hoc test. In addition, urine albu-
min excretion and fasting blood glucose levels were assessed by using a two-way analysis of variance. Tests were 
performed with GraphPad Prism 5 (GraphPad Soſtware, La Jolla, CA). P-value < 0.05 was considered significant.
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